C
Chad R. Messick
Researcher at University of Illinois at Chicago
Publications - 13
Citations - 235
Chad R. Messick is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Gentamicin & Cefoxitin. The author has an hindex of 9, co-authored 13 publications receiving 227 citations. Previous affiliations of Chad R. Messick include Veterans Health Administration & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Levofloxacin and Sparfloxacin: New Quinolone Antibiotics
TL;DR: Clinical trials confirm that these new quinolones are as effective as traditional therapies for the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, urinary tract infections, acute gonococcal and nongonococcal urethritis, and skin and skin structure infections.
Journal ArticleDOI
In-vitro activity of polyhexamethylene biguanide (PHMB) against fungal isolates associated with infective keratitis
Chad R. Messick,Susan L. Pendland,Majid Moshirfar,Richard G. Fiscella,Karen J. Losnedahl,Christopher A. Schriever,Paul C. Schreckenberger +6 more
TL;DR: Polyhexamethylene biguanide (PHMB), which is currently used as an environmental biocide and contact lens disinfectant, has been shown to have excellent in-vitro activity against a broad range of fungal pathogens and to be effective and well tolerated at concentrations of 200 mg/L when used as treatment of patients with keratitis.
Journal ArticleDOI
Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.
Mark H. Gotfried,Mark H. Gotfried,Rose Jung,Chad R. Messick,Israel Rubinstein,Kevin W. Garey,Keith A. Rodvold,Larry H. Danziger +7 more
TL;DR: 6-week clarithromycin 500 mg BID was clinically effective in allowing a reduction in prednisone dosage, without worsening pulmonary function, QOL, or asthmatic symptoms, in patients with corticosteroid-dependent asthma.
Journal ArticleDOI
Polyhexamethylene biguanide (phmb) in the treatment of experimental fusarium keratomycosis
Richard G. Fiscella,Majid Moshifar,Chad R. Messick,Susan L. Pendland,John W. Chandler,Marlos A. G. Viana +5 more
TL;DR: Whether topical polyhexamethylene biguanide (PHMB) 0.02% was effective in significantly reducing the fungal growth in the rabbit model of Fusarium keratomycosis in rabbits is investigated.
Journal ArticleDOI
In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa
TL;DR: Predominantly additive effects were seen with all combinations, with no significant differences detected between the fluoroquinolone agents.